glp 1 and kidney disease GLP-1 receptor agonists are increasingly used to treat type 2 diabetes obesity, and trials have shown reductions in cardiovascular risk and slowing of failure. Adverse events are mostly gastrointestinal Design and discovery of a

Metformin Evidence: Long-term studies (including the TAME trial) show improved cardiovascular health, reduced inflammation, and lower all-cause mortality in diabetics

Also boosts collagen production

the clinical significance in humans remains under investigation and is not yet established for retatrutide specifically [24] [25] Other class-associated cautions: Based on the broader GLP-1/GIP receptor agonist class, potential effects on gallbladder function and delayed gastric emptying are relevant considerations, though evidence specific to retatrutide is still emerging It is important to note that this evidence derives from early-phase trials conducted under controlled conditions with medical supervision

There is no well-established dosage